BioDlink International Company Limited
HKSE: 1875.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shan Fu
- Employees
- 611
- Headquarters
- Suzhou, China
- IPO year
- 2019
- Market cap
- HK$3.6B
- Website
- https://www.totbiopharm.com.cn
Loading 1875…
Loading profile data…Frequently asked questions about 1875
What does BioDlink International Company Limited (1875.HK) do?
BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009 and is headquartered in Suzhou, China.
Where does 1875.HK trade?
BioDlink International Company Limited (1875.HK) trades on the Hong Kong Stock Exchange.
What sector is 1875.HK in?
BioDlink International Company Limited (1875.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioDlink International Company Limited?
Shan Fu is the chief executive officer of BioDlink International Company Limited (1875.HK).
Where is BioDlink International Company Limited headquartered?
BioDlink International Company Limited is headquartered in China.
Does 1875.HK pay a dividend?
BioDlink International Company Limited (1875.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1875.HK go public?
BioDlink International Company Limited (1875.HK) completed its initial public offering in 2019.